Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV golimumab in active ankylosing spondylitis
2014-000241-74Phase 3Completed
- Sponsor
- Janssen Biologics B.V.
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Golimumab IV with Placebo IV (2 arms). Primary endpoint: ASAS20 response at week 16. Started Oct 2014; status: completed.
02
Drugs
golimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2014-000241-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000241-74.